2 completed, 1 active not recruiting, 1 withdrawn. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow Talimogene laherparepvec (T-Vec): new trials by email Literature Review of Talimogene laherparepvec (T-Vec) trials Research Report on Talimogene laherparepvec (T-Vec)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 | |
| TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion) Talimogene laherparepvec (T-VEC) - Melanoma and Sarcoma | Phase 1 / Phase 2 | Completed | Royal Marsden NHS Foundation Trust | 15 | 2018-06-26 | 2021-08-18 |
| T-VEC in Non-melanoma Skin Cancer Talimogene Laherparepvec (T-VEC) - Non-melanoma Skin Cancer, Basal Cell Carcinoma | Phase 1 | Completed | University of Zurich | 26 | 2018-04-19 | 2022-03-18 |
| A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Talimogene Laherparepvec (T-VEC), Pembrolizumab - Sarcoma, Epithelioid Sarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 41 | 2017-03-03 | 2026-07-17 |
Melanoma (2) · Sarcoma (2) · Carcinoma, Basal Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Squamous Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Neoplasm Metastasis (1) · Skin Neoplasms (1)
Memorial Sloan Kettering Cancer Center (1) · Royal Marsden NHS Foundation Trust (1) · TriHealth Inc. (1) · University of Zurich (1)
United States (2) · Switzerland (1) · United Kingdom (1)
Andrew Hayes (1) · Ciara Kelly, MBBCh BAO (1) · Reinhard Dummer, Prof. Dr. (1)